CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

International Normalized Point of Care Testing for Patients on Anticoagulant Therapies: Clinical Utility and Cost-Effectiveness

Last updated: April 27, 2020
Project Number: RB1466-000
Product Line: Rapid Response
Research Type: Device
Report Type: Summary of Abstracts
Result type: Report

Question

  1.  What is the clinical utility of international normalized ratio point of care testing for patients on anticoagulation therapies?
  2. What is the cost-effectiveness of international normalized ratio point of care testing for patients on anticoagulation therapies?

Key Message

Nine non-randomized studies were identified regarding the clinical utility of international normalized ratio point of care testing for patients on anticoagulation therapies. No relevant economic evaluations were identified regarding the cost-effectiveness of international normalized ratio point of care testing for patients on anticoagulation therapies.